{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:36:25Z","timestamp":1788986185416,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>With increasing antimicrobial resistance, antibiotic treatment options for neonatal late-onset sepsis (LOS) are becoming limited. Primary objective of this study was assessment of the safety of ceftaroline fosamil in LOS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Eligible neonates and very young infants 7 to &lt;60 days of age with LOS were enrolled in this phase 2, open-label, multicenter study (NCT02424734) and received ceftaroline fosamil 4 or 6\u2009mg\/kg every 8 hours by 1-hour intravenous infusion plus intravenous ampicillin and optional aminoglycoside for 48 hours\u221214 days. Safety was assessed through the final study visit (21\u201335 days after the last study therapy dose). Efficacy, assessed as clinical and microbiologic response, was evaluated at end-of-treatment and test-of-cure. Pharmacokinetic samples were collected via sparse-sampling protocol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eleven patients [54.5% male, median (range) age 24 (12\u201353) days] were enrolled and received ceftaroline fosamil for a median (range) duration of 8 (3\u201315) days. Ten adverse events (AEs) occurred in 5 (45.5%) patients (safety population); most frequent AE was diarrhea (n = 2). All except 1 AE (diarrhea) were nontreatment-related. Predominant baseline pathogen was <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>. No patients were clinical failures at end-of-treatment\/test-of-cure. Observed sparse steady-state pharmacokinetics data (19 samples) were comparable to previous pediatric data and generally within 90% model prediction intervals; neonatal probability of target attainment was &gt;95% based on established pharmacokinetic\/pharmacodynamic targets.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Safety in neonates and very young infants was consistent with the known ceftaroline fosamil safety profile. These results support the use of ceftaroline fosamil (6\u2009mg\/kg every 8 hours) as a potential treatment option for LOS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002607","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T19:25:47Z","timestamp":1582313147000},"page":"411-418","source":"Crossref","is-referenced-by-count":29,"title":["Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis"],"prefix":"10.1097","volume":"39","author":[{"given":"John S.","family":"Bradley","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Rady Children\u2019s Hospital\/University of California San Diego School of Medicine, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[{"name":"Microbiology, Internal Medicine, Pfizer, Groton, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phylinda L. S.","family":"Chan","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pfizer, Sandwich, Kent, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan R.","family":"Raber","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pfizer, La Jolla, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Riccobene","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mas Casullo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Allergan plc, Madison, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Li","family":"Yan","sequence":"additional","affiliation":[{"name":"Biostatistics, Pfizer, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Hendrick","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Pfizer, Sandwich, Kent, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hammond","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Pfizer, Collegeville, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi K.","family":"Leister-Tebbe","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Pfizer, Collegeville, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/S0140-6736(10)60549-1","article-title":"Global, regional, and national causes of child mortality in 2008: a systematic analysis.","volume":"375","author":"Black","year":"2010","journal-title":"Lancet"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jpeds.2011.12.023","article-title":"Clinical sepsis in neonates and young infants, United States, 1988-2006.","volume":"160","author":"Lukacs","year":"2012","journal-title":"J Pediatr"},{"key":"R3-20230912","first-page":"997","article-title":"Current management of late onset neonatal bacterial sepsis in five European countries.","volume":"173","author":"Lutsar","year":"2014","journal-title":"Eur J Pediatr"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pedneo.2015.09.007","article-title":"Early and late infections in newborns: where do we stand? A review.","volume":"57","author":"Cortese","year":"2016","journal-title":"Pediatr Neonatol"},{"key":"R5-20230912","first-page":"154","article-title":"Aetiology of community-acquired neonatal sepsis in low and middle income countries.","volume":"1","author":"Waters","year":"2011","journal-title":"J Glob Health"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"F4","DOI":"10.1136\/adc.2009.178483","article-title":"Empirical treatment of neonatal sepsis: are the current guidelines adequate?","volume":"96","author":"Muller-Pebody","year":"2011","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"712150","DOI":"10.1155\/2011\/712150","article-title":"Choice and duration of antimicrobial therapy for neonatal sepsis and meningitis.","volume":"2011","author":"Sivanandan","year":"2011","journal-title":"Int J Pediatr"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.clp.2010.06.004","article-title":"Antibiotic resistance in neonatal intensive care unit pathogens: mechanisms, clinical impact, and prevention including antibiotic stewardship.","volume":"37","author":"Patel","year":"2010","journal-title":"Clin Perinatol"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.00330-12","article-title":"Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.","volume":"56","author":"Flamm","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/jcph.809","article-title":"Population PK modeling and target attainment simulations to support dosing of ceftaroline fosamil in pediatric patients with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.","volume":"57","author":"Riccobene","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000001160","article-title":"A multicenter, randomized, observer-blinded, active-controlled study evaluating the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community-acquired bacterial pneumonia.","volume":"35","author":"Blumer","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/INF.0000000000001159","article-title":"A randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline versus ceftriaxone.","volume":"35","author":"Cannavino","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/INF.0000000000001191","article-title":"A multicenter, randomized, observer-blinded, active-controlled study to evaluate the safety and efficacy of ceftaroline versus comparator in pediatric patients with acute bacterial skin and skin structure infection.","volume":"35","author":"Korczowski","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"RR-10","key":"R21-20230912","first-page":"1","article-title":"Prevention of perinatal group B streptococcal disease\u2013revised guidelines from CDC, 2010.","volume":"59","author":"Verani","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MOP.0000000000000338","article-title":"Adverse consequences of neonatal antibiotic exposure.","volume":"28","author":"Cotten","year":"2016","journal-title":"Curr Opin Pediatr"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"F257","DOI":"10.1136\/archdischild-2014-306213","article-title":"Late-onset neonatal sepsis: recent developments.","volume":"100","author":"Dong","year":"2015","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/INF.0000000000000542","article-title":"Prospective surveillance of antibiotic use in the neonatal intensive care unit: results from the SCOUT study.","volume":"34","author":"Cantey","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl 4","key":"R25-20230912","first-page":"35","article-title":"Use and misuse of antibiotics in the neonatal intensive care unit.","volume":"25","author":"Tzialla","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0033-1361933","article-title":"Medication use in the neonatal intensive care unit.","volume":"31","author":"Hsieh","year":"2014","journal-title":"Am J Perinatol"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00148581-200305110-00002","article-title":"Neonatal sepsis: epidemiology and management.","volume":"5","author":"Baltimore","year":"2003","journal-title":"Paediatr Drugs"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1128\/AAC.01718-13","article-title":"Determination of vancomycin pharmacokinetics in neonates to develop practical initial dosing recommendations.","volume":"58","author":"Kim","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"e77169","DOI":"10.1371\/journal.pone.0077169","article-title":"Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis.","volume":"8","author":"Ye","year":"2013","journal-title":"PLoS One"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1128\/AAC.49.7.2760-2766.2005","article-title":"Population pharmacokinetics of cefepime in the neonate.","volume":"49","author":"Capparelli","year":"2005","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:56:42Z","timestamp":1694559402000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002607","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}